HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Guanfacine (Tenex)

A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

Also Known As:

Tenex; BS-100-141; Estulic; Guanfacine Hydrochloride; Guanfacine Monohydrochloride; Lon798; BS 100 141; BS100141; Hydrochloride, Guanfacine; Monohydrochloride, Guanfacine; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-

Networked: 283 relevant articles (43 outcomes, 50 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Carboxylic Acids: 83
  - Carbocyclic Acids
    - Phenylacetates
      - Guanfacine: 283
- Amidines: 11
  - Guanidines: 20
    - Guanfacine: 283

Experts

1.	Lyne, Andrew: 14 articles (11/2015 - 04/2007)
2.	Sikirica, Vanja: 9 articles (11/2015 - 05/2012)
3.	Newcorn, Jeffrey H: 6 articles (11/2015 - 01/2003)
4.	McBurnett, Keith: 5 articles (10/2014 - 01/2008)
5.	Arnsten, Amy F T: 5 articles (08/2014 - 07/2002)
6.	Wu, Eric Q: 5 articles (11/2013 - 05/2012)
7.	Sallee, Floyd R: 5 articles (11/2013 - 02/2009)
8.	Xie, Jipan: 5 articles (11/2013 - 05/2012)
9.	Scahill, Lawrence: 4 articles (12/2015 - 11/2005)
10.	Youcha, Sharon: 4 articles (04/2015 - 01/2012)

Related Diseases

1.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/01/2008 - "All groups of children taking guanfacine extended release showed significant improvement on hyperactivity/impulsivity and inattentiveness subscales of the Attention-Deficit/Hyperactivity Disorder Rating Scale IV, Clinical Global Impression of Improvement, Parent's Global Assessment, Conners' Parent Rating Scale-Revised: Short Form, and Conners' Teacher Rating Scale-Revised: Short Form assessments compared with placebo. " 10/01/2014 - "In this post hoc analysis, we assessed whether guanfacine extended-release (GXR) adjunctive to a psychostimulant resulted in greater response and remission rates than placebo + psychostimulant in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). " 09/01/2007 - "Guanfacine hydrochloride is an alpha(2a)-adrenoreceptor agonist found to be effective in the treatment of attention-deficit/hyperactivity disorder (ADHD). " 11/01/2013 - "Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents." 10/01/2014 - "The purpose of this study was to evaluate the efficacy of once-daily guanfacine extended release (GXR) monotherapy administered either in the morning or evening, using a modified Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S) assessed three times/day in children with attention-deficit/hyperactivity disorder (ADHD). "
2.	Hypertension (High Blood Pressure) 08/01/1982 - "This study demonstrated the efficacy of guanfacine monotherapy in hypertension and suggests that the normalization rate of blood pressure levels does not further increase with daily doses higher than 4 mg." 01/01/1991 - "Estulic tablet proved to be effective in form of monotherapy especially in the treatment of mild hypertension, in form of combination therapy in hypertension of medium severity. " 01/01/1989 - "Guanfacine monotherapy was effective in 75% of patients with moderate hypertension (using low doses 1-3 mg/day). " 01/01/1981 - "It is considered that guanfacine is a useful new antihypertensive drug, effective in mild hypertension, and side-effects are few if doses are maintained below 3 mg daily. " 07/01/1982 - "[Efficacy of guanfacine in the treatment of arterial hypertension]."
3.	Renal Insufficiency (Renal Failure) 03/28/1986 - "Based on pharmacokinetic studies in these target groups and on the dual renal and nonrenal clearance of guanfacine, the drug may, most probably, be administered to elderly patients and patients with renal insufficiency without dosage adjustment." 01/01/1989 - "The steady-state pharmacokinetics and renal clearance of guanfacine were studied in patients with renal insufficiency. " 01/01/1987 - "Human pharmacokinetic studies in patients with renal failure indicate that due to an increase in metabolic clearance and increase in non-renal elimination of the drug guanfacine may be administered to elderly patients and patients with renal impairment without dosage adjustment." 01/01/1980 - "[Pharmacokinetic study of guanfacine in patients with renal insufficiency and in patients under chronic dialysis (author's transl)]." 01/01/1989 - "Higher plasma levels of guanfacine were observed in patients with GFR less than 30 ml/min. The steady state t 1/2 of guanfacine in the presence of renal insufficiency was insignificantly prolonged relative to that observed in the presence of normal renal function and appeared to be independent of the degree of renal insufficiency."
4.	Tic Disorders (Tic Disorder) 07/01/2001 - "Guanfacine appears to be a safe and effective treatment for children with tic disorders and ADHD." 11/01/2005 - "Results of this open-label study add to the growing data base on the safety and efficacy of guanfacine in children with ADHD and tic disorders." 11/01/2005 - "An open-label, prospective study of guanfacine in children with ADHD and tic disorders." 07/01/2001 - "Subjects from a specialty tic disorders clinic were randomly assigned to receive 8 weeks of treatment with guanfacine or placebo under double-blind conditions. " 07/01/2001 - "This study evaluated the efficacy and safety of guanfacine in treating children with tic disorders and attention deficit hyperactivity disorder (ADHD). "
5.	Tics (Tic) 11/01/2005 - "At an average dose of 2.0 +/- 0.6 mg/ day, guanfacine was associated with mean improvement of 27% on the Hyperactivity Index (N = 25; t = 4.61; p < 0.001), 32% on the total score of the teacher-rated ADHD Scale (N = 19; t = 5.27; p < 0.001), and 39% on the total tic severity scale (N = 19; t = 4.17; p < 0.001). " 07/01/2001 - "Tic severity decreased by 31% in the guanfacine group, compared to 0% in the placebo group. " 09/01/1995 - "Guanfacine may provide a safe alternative therapy for children with ADHD in the presence of tics. " 09/01/1995 - "In addition, guanfacine caused a significant decrease in severity of motor (p < .02) and phonic (p < .02) tics as measured by the TSSR and the YGTSS, respectively. " 07/01/1997 - "It may be reasonable to initiate a trial of guanfacine in a patient who has not responded to or cannot tolerate other agents due to adverse effects or drug dependence, or in a patient who develops motor tics. "

Related Drugs and Biologics

1.	Clonidine (ST 155)
2.	Methyldopa (Aldomet)
3.	atomoxetine (Strattera)
4.	Naltrexone (ReVia)
5.	Growth Hormone (Somatotropin)
6.	Aldosterone
7.	Dextroamphetamine (Dexedrine)
8.	TEMPO
9.	Prazosin (Minipress)
10.	Xylazine (Xylazin)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Injections
3.	Analgesia
4.	Oral Administration
5.	Ligation